The Global neutropenia drugs market is anticipated to grow at a CAGR of 5.0% during the forecast period. The major factors for growth of the market include the increasing prevalence of cancer cases along with increasing investment in R&D by companies, to develop various novel therapies for the treatment of this disease, which will fuel the growth of the market during the forecast period.

Neutropenia is a disease where the number of white blood cells (neutrophils) present in the blood are reduced significantly, further hampering the immune system of the patient. In 2019, 9.8 million new cancer patients received chemotherapy treatment, according to the Lancet Oncology journal. The chemotherapy affects the count of WBCs, as some of them die during the treatment. This aspect will further grow the demand of the market during the forecast period. According to the WHO around more than 15 million patients will go under chemotherapy treatment by 2040.  According to the International Agency for Research on Cancer, in 2018, 169,270 people  were living with leukemia and 58,876 new leukemia cases were diagnosed in North America. In February 2018, Partner Therapeutics, a Boston-based cancer company, acquired Leukine (Sargramostim) from Sanofi for $60 million, which is used for the treatment of leukemia. Some of the key global players in theneutropenia drugs marketinclude Teva Pharmaceutical, Amgen, Sanofi, Mylan, Kyowa Kirin, Baxter International, and many others.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By  Treatment 

o By  Distribution Channel

• Competitive Landscape -Teva Pharmaceutical, Amgen, Sanofi, Mylan, Kyowa Kirin, Baxter International, and many others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Globalneutropenia drugs market 

o By Treatment

• Colony-stimulation factor
• Antibiotics
• Antifungal
• Antiviral

o By Distribution Channels

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies 

Regions Covered